Latest Breaking News On - Center ophthalmology associates - Page 1 : vimarsana.com

Three new studies show low-dose atropine can help slow myopia in children

Myopia, or nearsightedness, is at an all-time high among children in the US. Globally, half the population is expected to be nearsighted by 2050.

Research Shows Low Dose Atropine Links to Slowing Myopia Progression in Children

Two studies presented at AAO demonstrate that low dose atropine is associated with slowing myopia progression, but another study finds that this is not true. Thus, there are mixed results on this relationship.

Research Shows Low Dose Atropine Links to Myopia Progression in Children

Case Challenges in nAMD and DME Management: Achieving Durable Response

healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

Anti-VEGF Conjugate Gets a Win in Retinal Vein Occlusion

Tarcocimab noninferior to aflibercept while cutting treatment burden in half

Kodiak Sciences Announces Upcoming Presentations of Tarcocimab Tedromer (KSI-301) Phase 3 BEACON Study Results in Retinal Vein Occlusion (RVO)

/PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative...

Kodiak Sciences Announces Upcoming Presentations of Tarcocimab Tedromer (KSI-301) Phase 3 BEACON Study Results in Retinal Vein Occlusion (RVO)

Kodiak Sciences Announces Upcoming Presentations of Tarcocimab Tedromer (KSI-301) Phase 3 BEACON Study Results in Retinal Vein Occlusion (RVO)

Kodiak Sciences Announces Upcoming Presentations of Tarcocimab Tedromer (KSI-301) Phase 3 BEACON Study Results in Retinal Vein Occlusion (RVO)

/PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative...

Retina Forum® 2021: Meeting the Vision of Reduced Treatment Burden in Neovascular Retinal Diseases - Session on Extending the Duration of Therapy

Activity Retina Forum® 2021: Meeting the Vision of Reduced Treatment Burden in Neovascular Retinal Diseases - Session on Extending the Duration of Therapy Educational Tools Activity Retina Forum® 2021: Meeting the Vision of Reduced Treatment Burden in Neovascular Retinal Diseases - Session on Extending the Duration of Therapy Educational Tools Certificate Retina Forum® 2021: Meeting the Vision of Reduced Treatment Burden in Neovascular Retinal Diseases - Session on Extending the Duration of Therapy This activity is supported by an educational grant from Genentech, Inc. 1.00 CME 60 MINS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on .